nach oben

Current Treatment Options in Neurology

Erschienen in:

01.10.2017 | Multiple Sclerosis and Related Disorders (P Villoslada, Section Editor)

Botulinum Toxin Treatment in Multiple Sclerosis—a Review

verfasst von: Yasaman Safarpour, MD, Tahereh Mousavi, MD, Bahman Jabbari, MD, FAAN

Erschienen in: Current Treatment Options in Neurology | Ausgabe 10/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review The purpose of this review is to provide updated information on the role of botulinum neurotoxin (BoNT) therapy in multiple sclerosis (MS). This review aims to answer which symptoms of multiple sclerosis may be amenable to BoNT therapy.

Recent findings We searched the literature on the efficacy of BoNTs for treatment of MS symptoms up to April 1st 2017 via the Yale University Library’s search engine including but not limited to Pub Med and Ovis SP. The level of efficacy was defined according to the assessment’s criteria set forth by the Subcommittee on Guideline Development of the American Academy of Neurology. Significant efficacy was found for two indications based on the available blinded studies (class I and II) and has been suggested for several others through open-label clinical trials.

Summary There is level A evidence (effective- two or more class I) that injection of BoNT-A into the bladder’s detrusor muscle improves MS-related neurogenic detrusor overactivity (NDO) and MS-related overactive (OA) bladder. There is level B evidence (probably effective- two class II studies) for utility of intramuscular BoNT-A injections for spasticity of multiple sclerosis. Emerging data based on retrospective class IV studies demonstrates that intramuscular injection of BoNTs may help other symptoms of MS such as focal tonic spasms, focal myokymia, spastic dysphagia, and double vision in internuclear ophthalmoplegia. There is no data on MS-related trigeminal neuralgia and sialorrhea, two conditions which have been shown to respond to BoNT therapy in non-MS population.

Dilokthornsakul P, Valuck RJ, Nair KV, Corboy JR, Allen RR, Campbell JD. Multiple sclerosis prevalence in the United States commercially insured population. Multiple sclerosis prevalence in the United States commercially insured population. Neurology. 2016;86:1014–21.CrossRefPubMedPubMedCentral

Zwibel HL, Smrtka J. Improving quality of life in multiple sclerosis: an unmet need. Am J Manag Care. 2011;17(Suppl 5 Improving):S139–45.PubMed

Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16:639–47.CrossRefPubMed

Botulinum Toxin-Therapeutic clinical practice and science. Jankovic, Albenese, Atassi, Dolly, Hallett, Mayer (Editors). 2009 Sanders-Elsevier Publisher, Philadelphia.

Montecucco C, Rasotto MB. On botulinum neurotoxin variability. MBio. 2015;6:e02131–14.CrossRefPubMedPubMedCentral

Rossetto O, Pirazzini M, Montecucco C. Botulinum neurotoxins: genetic, structural and mechanistic insights. Nat Rev Microbiol. 2014;12:535–49.CrossRefPubMed

Lance JW. The control of muscle tone, reflexes, and movement: Robert Wartenberg Lecture. Neurology. 1980;30:1303–13.CrossRefPubMed

Gracies JM. Pathophysiology of spastic paresis. I: paresis and soft tissue changes. Muscle Nerve. 2005;31(5):535–51.CrossRefPubMed

Gracies JM. Pathophysiology of spastic paresis. II: emergence of muscle over activity. Muscle Nerve. 2005;31(5):552–71.CrossRefPubMed

10.

Gioux M, Petit J. Effects of immobilizing the cat peroneus longus muscle on the activity of its own spindles. J Appl Physiol (1985). 1993;31(5):552–71.

11.

Crone C, Johnsen LL, Biering-Srensen F, Nielsen JB. Appearance of reciprocal facilitation of ankle extensors from ankle flexors in patients with stroke or spinal cord injury. Brain. 2003;126(pt 2):495–507.CrossRefPubMed

12.

Kheder A, Nair KPS. Spasticity: pathophysiology, evaluation and management. Pract Neurol. 2012;12:289–98.CrossRefPubMed

13.

Yelnik AP, Simon O, Paratte B, et al. How to clinically assess and treat muscle overactivity in spastic paresis. J Rehabil Med. 2010;42:801–7.CrossRefPubMed

14.

Pozzilli C. Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice. Expert Rev Neurother. 2013;13(12 Supple):49–54.CrossRefPubMed

15.

Rizzo MA. Hadjimichael OC, preingerova J, Vollmer TL, prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10:589–95.CrossRefPubMed

16.

Zwibel HL. Contribution of impaired mobility and general symptoms to the burden of multiple sclerosis. Adv Ther. 2009;26(12):1043–57.CrossRefPubMed

17.

Martin A, Abogunrin S, Kurth H, Dinet J. Epidemiological, humanistic, and economic burden of illness of lower limb spasticity in adults: a systematic review. Neuropsychiatr Dis Treat. 2014;10:111–22.PubMedPubMedCentral

18.

Flachenecker P, Henze T, Zettl UK. Spasticity in patients with multiple sclerosis—clinical characteristics, treatment and quality of life. Acta Neurol Scand. 2014;129(3):154–62.CrossRefPubMed

19.

Snow BJ, Tsui JK, Bhatt MH, Varelas M, Hashimoto SA, Calne DB. Treatment of spasticity with botulinum toxin: a double-blind study. Ann Neurol. 1990;28:512–5.CrossRefPubMed

20.

Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology. 1995;45:712–7.CrossRefPubMed

21.

•• Hyman N, Barnes M, Bhakta B, Cozens A, Bakheit M, Kreczy-Kleedorfer B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry. 2000;68:707–12. This is the first double blind, placebo controlled study which demonstrated improvement of adductor spasticity after BoNT therapy in a sizeable number of patients with multiple sclerosis.

22.

Phadke CP, Davidson C, Ismail F, Boulias C. The effect of neural lesion type on botulinum toxin dosage: a retrospective chart review. PM R. 2014;6:406–11.CrossRefPubMed

23.

Schramm A, Ndayisaba JP, Auf dem Brinke M, Hecht M, Herrmann C, Huber M, et al. Spasticity treatment with onabotulinumtoxin A: data from a prospective German real-life patient registry. J Neural Transm (Vienna). 2014;121:521–30.

24.

Nuanthaisong U, Abraham N, Goldman HB. Incidence of adverse events after high doses of onabotulinumtoxinA for multiple indications. Urology. 2014;84:1044–8.CrossRefPubMed

25.

• Dressler D, Bhidayasiri R, Bohlega S. Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. J Neurol. 2017;264:112–20. This recent publication indicates that a European task force after reviewing world literature recommends BoNT therapy for treatment of spasticity in multiple sclerosis.CrossRefPubMed

26.

Yonnet GJ, Fjeldstad AS, Carlson NG, Rose JW. Advances in the Management of Neurogenic detrusor overactivity in multiple sclerosis. Int J MS Case. 2013;15:66–72.CrossRef

27.

Holstege G. Descending motor pathways and spinal motor system. Limbic and non-limbic components. Prog Brain research. 1991;87:307–421.CrossRefPubMed

28.

Griffiths D. Neural control of micturition in humans: a working model. Nat Rev Urol. 2015;12:695–705.CrossRefPubMed

29.

Ruffion A, Castro-Diaz D, Patel H, Khalaf K, Onyenwenyi A, Globe D, et al. Systematic review of the epidemiology of urinary incontinence and detrusor overactivity among patients with neurogenic overactive bladder. Neuroepidemiology. 2013;41:146–55.CrossRefPubMed

30.

Mahajan ST, Patel PB, Marrie RA. Under treatment of overactive bladder symptoms in patients with multiple sclerosis: an ancillary analysis of the NARCOMS patient registry. J Urol. 2010;183:1432–7.CrossRefPubMed

31.

Wintner A, Kim MM, Bechis SK, Kreydin EI. Voiding dysfunction in multiple sclerosis. Semin Neurol. 2016;36:34–40.CrossRefPubMed

32.

de Sèze M, Ruffion A, Denys P, Joseph PA, Perrouin-Verbe B, GENULF. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13:915–28.CrossRefPubMed

33.

Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80:470–7.PubMed

34.

Carpenter FG. Motor responses of the urinary bladder and skeletal muscle in botulinum intoxicated rats. J Physiol. 1967;188:1–11.CrossRefPubMedPubMedCentral

35.

Schurch B, Hauri D, Largo M, Kreienbühl B, Meyer E, Rossier AB. Effects of botulinum A toxin on the periurethral striated sphincter of the neurogenic bladder. Preliminary study. J Urol (Paris). 1990;96:375–80.

36.

Dykstra DD, Sidi AA. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study. Arch Phys Med Rehabil. 1990;71:24–6.PubMed

37.

Cruz F, Herschorn S, Aliotta P, Brin M, Thompson C, Lam W, et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60:742–50.

38.

•• Ginsberg D, Gousse A, Keppenne V, Sievert KD, Thompson C, Lam W, et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187:2131–9. This phase 3 blinded study shows efficacy, safety and tolerability of OnaBoNT-A treatment in improving bladder symptoms of detrusor hyperactivity in multiple sclerosis.

39.

Schurch B, de Sèze M, Denys P, Chartier-Kastler E, Haab F, Everaert K, et al. Botox detrusor hyperreflexia study team. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174:196–200.

40.

Herschorn S, Gajewski J, Ethans K, Corcos J, Carlson K, Bailly G, et al. Efficacy of botulinum toxin A injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. Efficacy of botulinum toxin a injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185:2229–35.

41.

Sussman D, Patel V, Del Popolo G, Lam W, Globe D, Pommerville P. Treatment satisfaction and improvement in health-related quality of life with onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity. Neurourol Urodyn. 2013;32:242–9.CrossRefPubMed

42.

Denys P, Del Popolo G, Amarenco G, Karsenty G, Le Berre P, Padrazzi B, Picaut P; Dysport Study Group. Efficacy and safety of two administration modes of an intra-detrusor injection of 750 units dysport® (abobotulinumtoxinA) in patients suffering from refractory neurogenic detrusor overactivity (NDO): A randomised placebo-controlled phase IIa study. Neurourol Urodyn. 2016;36:457–62

43.

Smith CP, Chancellor MB. Botulinum toxin to treat neurogenic bladder. Semin Neurol. 2016;36:5–9.CrossRefPubMed

44.

Gallien P, Reymann JM, Amarenco G, Nicolas B, de Sèze M, Bellissant E. Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. J Neurol Neurosurg Psychiatry. 2005;76:1670.CrossRefPubMedPubMedCentral

45.

Foley PL, Vesterinen HM, Laird BJ, Sena ES, Colvin LA, Chandran S, et al. Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis. Pain. 2013;154:632–42.

46.

Truini A, Barbanti P, Pozzilli C, Cruccu G. A mechanism-based classification of pain in multiple sclerosis. J Neurol. 2013;260:351–67.CrossRefPubMed

47.

Nurmikko TJ, Gupta S, Maclver K. Multiple sclerosis-related central pain disorders. Curr Pain Headache Rep. 2010;14:189–95.CrossRefPubMed

48.

Al-Araji AH, Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler. 2005;11:398–402.CrossRefPubMed

49.

Mueller D, Obermann M, Yoon MS, et al. Prevalence of trigeminal neuralgia and persistent idiopathic facial pain: a population-based study. Cephalalgia. 2011;31:1542–8.CrossRefPubMed

50.

Broggi G, et al. Operative findings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery. 2004;55:830–8. discussion 838–839 CrossRefPubMed

51.

Katusic S, Williams DB, Beard CM, Bergstralh EJ, Kurland LT. Epidemiology and clinical features of idiopathic trigeminal neuralgia and glossopharyngeal neuralgia similarities and differences, Rochester, Minnesota, 1945-1984. Neuroepidemiology. 1991;10:276–81.CrossRefPubMed

52.

Cruccu G, Finnerup NB, Jensen TS, Scholz J, Sindou M, Svensson P, et al. Trigeminal neuralgia: new classification and diagnostic grading for practice and research. Neurology. 2016;87:220–8.CrossRefPubMedPubMedCentral

53.

Cruccu G, Gronseth G, Alksne J, et al. AANEFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008;15:1013–28.CrossRefPubMed

54.

Meng J, Wang J, Lawrence G, Dolly JO. Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential. J Cell Sci. 2007;120(16):2864–74.CrossRefPubMed

55.

Cui M, Khanijou S, Rubino J, Aoki KR. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107:125–33.CrossRefPubMed

56.

Shin MC, Wakita M, Xie DJ, et al. Inhibition of membrane Na+ channels by a type botulinum toxin at femtomolar concentrations in central and peripheral neurons. J Pharmacol Sci. 2012;118:33–42.CrossRefPubMed

57.

Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D. Subcutaneous injection of botulinum toxin A is beneficial in Postherpetic neuralgia. Pain Med. 2010;11:1827–33.CrossRefPubMed

58.

Ranoux DA, Attal N, Morain F, Bouhassira D. Botulinum toxin type a induces direct analgesic effects in chronic neuropathic pain. Ann Neurol. 2008;64:274–83.CrossRefPubMed

59.

Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, et al. Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72:1473–8.CrossRefPubMed

60.

Wu CJ, Lian YJ, Zheng YK, et al. Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia. 2012;32:443–50.

61.

Zuniga C, Piedimonte F, Diaz S, Micheli F. Acute treatment of trigeminal neuralgia with onabotulinum toxin A. Clin Neuropharmacol. 2013;36:146–50.CrossRefPubMed

62.

Shehata HS, El-Tamawy MS, Shalaby NM, Ramzy G. Botulinum toxin-type A: could it be an effective treatment option in intractable trigeminal neuralgia? J Headache Pain. 2013;14:92.CrossRefPubMedPubMedCentral

63.

Zhang H, Lian Y, Ma Y, et al. Two doses of botulinum toxin type A for the treatment of trigeminal neuralgia: observation of therapeutic effect from a randomized, double-blind, placebo-controlled trial. J Headache Pain. 2014;15:65.CrossRefPubMedPubMedCentral

64.

Shaikh A, Phadke CP, Ismail F, Boulias C. Relationship between botulinum toxin, spasticity, and pain: a survey of patient perception. Can J Neurol Sci. 2016;43:311–5.CrossRefPubMed

65.

Marco E, Duarte E, Vila J, Tejero M, Guillen A, Boza R, et al. Is botulinum toxin type A effective in the treatment of spastic shoulder pain in patients after stroke? A double-blind randomized clinical trial. Rehabil Med. 2007;39:440–7.CrossRef

66.

Shaw LC, Price CI, Van Wijck FM, Shackley P, Steen N, Barnes MP, et al., BoTULS investigators. Botulinum toxin for the upper limb after stroke (BoTULS) trial: effect on impairment, activity limitation, and pain. Stroke. 2011;42:1371–9.

67.

Rosales RL, Kong KH, Goh KJ, Kumthornthip W, Mok VC, Delgado-De Los Santos MM, et al. Botulinum toxin injection for hypertonicity of the upper extremity within 12 weeks after stroke: a randomized controlled trial. Neurorehabil Neural Repair. 2012;26:812–21.CrossRefPubMed

68.

Dodick DW, Turkel CC, DeGryse RE, Aurora SK, Silberstein SD, Lipton RB, et al., PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50:921–36.

69.

Moisset X, Ouchchane L, Guy N, Bayle DJ, Dallel R, Clavelou P. Migraine headaches and pain with neuropathic characteristics: comorbid conditions in patients with multiple sclerosis. Pain. 2013;154:2691–9.CrossRefPubMed

70.

Gelfand AA, Gelfand JM, Goadsby PJ. Migraine and multiple sclerosis: epidemiology and approach to treatment. Mult Scler Relat Disord. 2013;2:73–9.CrossRefPubMed

71.

Shibasaki H, Kuroiwa Y. Painful tonic seizures in multiple sclerosis. Arch Neurol. 1974;30:47–51.CrossRefPubMed

72.

Restivo DA, Tinazzi M, Patti F, Palmeri A, Maimone D. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology. 2003;61:719–20.CrossRefPubMed

73.

Meador W, Salter AR, Rinker JR II. Symptomatic management of multiple sclerosis-associated tremor among participants in the NARCOMS registry. Int J MS Care. 2016;18:147–53.CrossRefPubMedPubMedCentral

74.

Koch M, Mostert J, Heersema D, et al. Tremor in multiple sclerosis. J Neurol. 2007;254:133–45.CrossRefPubMedPubMedCentral

75.

Koller WC. Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol. 1984;41:280–1.CrossRefPubMed

76.

Jankovic J, Schwartz K, Clemence W, Aswad A, Mordaunt J. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996;11:250–6.CrossRefPubMed

77.

Rahimi F, Bee C, Debicki D, Roberts AC, Bapat P, Jog M. Effectiveness of BoNT A in Parkinson's disease upper limb tremor management. Can J Neurol Sci. 2013;40:663–9.CrossRefPubMed

78.

Clarke CE. Botulinum toxin type A in cerebellar tremor caused by multiple sclerosis. Eur J Neurol. 1997;4:68–71.CrossRefPubMed

79.

Gutmann L, Gutmann L. Myokymia and neuromyotonia. J Neurol. 2004;251:138–42.CrossRefPubMed

80.

Andermann F, Cosgrove JBR, Lloyd-Smith DL, Gloor P, McNaughton FL. Facial myokymia in multiple sclerosis. Brain. 1961;84:31–44.CrossRef

81.

Jacobs L, Kaba S, Pullicino P. The lesion causing continuous facial myokymia in multiple sclerosis. Arch Neurol. 1994;51:1115–9.CrossRefPubMed

82.

Sedano MJ, Trejo JM, Macarrón JL, Polo JM, Berciano J, Calleja J. Continuous facial myokymia in multiple sclerosis: treatment with botulinum toxin. Eur Neurol. 2000;43:137–40.CrossRefPubMed

83.

Gutmann L, Brick JF, Riggs JE. Calcium and myokymia of brainstem origin. Neurology. 1986;36:26–30.

84.

Habek M, Adamec I, Gabelić T, Brinar VV. Treatment of facial myokymia in multiple sclerosis with botulinum toxin. Acta Neurol Belg. 2012;112:423–4.CrossRefPubMed

85.

• Restivo DA, Marchese-Ragona R, Patti F, Solaro C, Maimone D, Zappalá G, et al. Botulinum toxin improves dysphagia associated with multiple sclerosis. Eur J Neurol. 2011;18:486–90. This prospective open label study demonstrates that injection of BoNTs into the cricoesophageal muscle can improve spastic dysphagia in patients with multiple sclerosis.CrossRefPubMed

86.

Alfonsi E, Restivo DA, Cosentino G, et al. Botulinum toxin is effective in the Management of Neurogenic Dysphagia.Clinical-electrophysiological findings and tips on safety in different eurological disorders. Front Pharmacol. 2017;8:80. doi:10.3389/fphar.2017.00080. eCollection 2017

87.

Murthy R, Dawson E, Khan S, Adams GG, Lee J. Botulinum toxin in the management of internuclear ophthalmoplegia. J AAPOS. 2007;11:456–9.CrossRefPubMed

88.

Hosp C, Naumann MK, Hamm H. Botulinum toxin treatment of autonomic disorders: focal hyperhidrosis and sialorrhea. Semin Neurol. 2016;36:20–8.

Titel: Botulinum Toxin Treatment in Multiple Sclerosis—a Review
verfasst von: Yasaman Safarpour, MD
Tahereh Mousavi, MD
Bahman Jabbari, MD, FAAN
Publikationsdatum: 01.10.2017
Verlag: Springer US
Erschienen in: Current Treatment Options in Neurology / Ausgabe 10/2017
Print ISSN: 1092-8480
Elektronische ISSN: 1534-3138
DOI: https://doi.org/10.1007/s11940-017-0470-5

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Was nützt die Kraniektomie bei schwerer tiefer Hirnblutung?

17.05.2024 Hirnblutung Nachrichten

Eine Studie zum Nutzen der druckentlastenden Kraniektomie nach schwerer tiefer supratentorieller Hirnblutung deutet einen Nutzen der Operation an. Für überlebende Patienten ist das dennoch nur eine bedingt gute Nachricht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen